Ibinini bivura Covid-19 byamaze kwemezwa n’igihugu cy’ubwongereza

Umuti Molnupiravir ukaba ukoze mu buryo w’ibinini wagaragaje ubushobozi bwo kuvura Covid-19 wemerewe gukoreshwa n’abarwaye icyo cyorezo mu Bwongereza.

Nkuko amabwiriza yo gukoresha uyu muti abivuga,ibi binini bizajya bihabwa abarwayi bazahajwe na Covid-19, umurwayi abihabwe inshuro ebyiri ku munsi, kandi yemerewe kubifata ari mu rugo.

Ikinyamakuru BBC cyatangaje ko ubushakashatsi bwakorewe kuri ibi binini, bwagaragaje ko bivura ibicurane, bikagabanyiriza uwarwaye Covid-19 n’izindi ndwara zisa nayo ibyago byo kujya mu bitaro cyangwa gupfa.

Sajid Javid, Minisitiri w’Ubuzima mu Bwongereza, yavuze ko ari inkuru nziza kuba igihugu cye aricyo cya mbere cyemeye ikoreshwa ry’ibyo binini ku barwariye Covid-19 mu ngo.

Ibigo nka Merck, Sharp and Dohme (MSD) na Ridgeback Biotherapeutics. nibyo byakoze ibi binini bya Molnupiravir   Ni byo binini bya mbere bivura Covid-19 byagiye hanze, aho kuba imiti isanzwe iterwa binyuze mu nshinge.

Molnupiravir akamaro kayo ni uko yinjira mu ntimatima ya virusi za Covid-19, ukazibuza kororoka binyuze mu guhindura imikorere yazo ku buryo ingano ya virusi ziba ziri mu mubiri ikomeza kuba nto, indwara igatakaza ubukana.Merck yatangaje ko hagikorwa ubushakashatsi kugira ngo uyu muti uzanagire ubushobozi bwo guhangana n’ubwoko bushya bwa Covid-19.

First pill to treat Covid gets approval in UK - BBC News

Uyu muti wemerewe gukoreshwa mu Bwongereza ku bantu bafite ibyago byo kuremba nk’abafite umubyibuho ukabije, izabukuru, diabète, umutima n’izindi.U Bwongereza bwatumije ibinini 480 000 bya molnupiravir. Ntabwo amafaranga byatanzweho yatangajwe.Ibindi bihugu birimo Australia, Singapore na Koreya y’Epfo nabyo byamaze gutumiza ibi binini.

 

Mushobora kudukurikirana ku mbuga nkoranyambaga zacu mukajya muba aba mbere mu kubona amakuru agezweho buri munsi.Kanda hano udukurikirane kuri Facebook, Kanda hano udukurikirane kuri Twitter cyangwa ukande hano ukore subscribe kuri Youtube.

 

Leave a Reply

Your email address will not be published. Required fields are marked *